JPRN-UMIN000045113招募中未知
euroimaging of ME/CFS - PET_ME
ational Center of Neurology and Psychiatry0 个研究点目标入组 90 人开始时间: 2021年8月10日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Malignancy Pregnancy Active infection
研究者
相似试验
招募中
不适用
euroimaging Research using MRpatients with psychiatric disordersJPRN-UMIN000004964Department of Neuropsychiatry, Faculty of Medical Sciences, University of Fukui40
进行中（未招募）
1 期
The use of FES-PET imaging as a tool to detect a possible reversion of Estrogen Receptor (ER)-a status in patients with metastatic breast cancer HER2 + and ERa neg treated with trastuzumab + pertuzumab + taxane.Metastatic breast cancer HER2 + and ERa neg.MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2018-001552-36-FRINSTITUT CLAUDIUS REGAUD33
招募中
不适用
euroimaging and physiological studies in psychiatric disorders with cognitive and emotional dysfunctiopsychiatric disorders with cognitive and emotional dysfunctionJPRN-UMIN000014257Yokohama City University200
招募中
不适用
Magnetic resonance imaging (MRI) for assessing fetal and neonatal brain development in the YOUth Cohort.Hersen-, neurocognitieve- en gedragsontwikkelingbehaviorbrainNL-OMON55467niversitair Medisch Centrum Utrecht100
终止
不适用
The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane.HER2-positive Breast CancerNCT03619044Institut Claudius Regaud4